Intravenous Immunoglobulin (IVIg): Market Research Report

March 2018 | 187 pages | ID: IF296766E13EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -

• Bharat Serums and Vaccines Limited
• Biotest AG
• China Biologic Products, Inc
• CSL Limited
• Grifols, S.A.
• Hualan Biological Engineering Inc.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Immunoglobulins to See Steady Growth

Table 1. Global Immunoglobulins Market by Segment (2017 & 2022): Percentage Breakdown of Market Value for Intravenous IG, Hyperimmunes and Subcutaneous IG (includes corresponding Graph/Chart)

Table 2. World Market for Immunoglobulins by Indication (2016): Percentage Breakdown of Market Value for CIDP, PI, Off-Label and Others (includes corresponding Graph/Chart)

Table 3. Leading Players in the Global Immunoglobulin Market (2016E): Percentage Breakdown of Market Value for CSL, Grifols, Octapharma, Shire and Others (includes corresponding Graph/Chart)

Intravenous Immunoglobulin – A Proliferating Biologic
Application Areas – A Brief Review
Market Outlook
Competitive Scenario

Table 4. Leading Players in the Global IVIg Market (2017E): Percentage Breakdown of Revenues for CSL, Grifols, Shire and Others (includes corresponding Graph/Chart)

2. MARKET TRENDS

Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
IVIg – The Mainstay of PI Therapy
Subcutaneous IG Formulations Gain Therapeutic Foothold

Table 5. Global Subcutaneous Immunoglobulin Market: 2016-2024 (includes corresponding Graph/Chart)

Hyperimmune Globulin – Taking IVIg Therapy a Step Ahead
Unsuccessful Clinical Trials for Alzheimer’s – A major Setback for IVIg Market
Synthetic Replacements to IVIg Therapy
IVIg Therapy – Home-based vs. Outpatient Settings
Per Capita Consumption Rate Varies Across Countries

Table 6. Global Intravenous Immunoglobulin Market (2016): Per Capita Consumption for Select Countries (in Kilograms per Million Inhabitants) (includes corresponding Graph/Chart)

Favorable Reimbursement and High Usage make US the Largest Consumer
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator

Table 7. Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart)

Table 8. Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart)

Table 9. Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)

Improving Healthcare Expenditure to Foster Growth

Table 10. Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart)

3. PLASMA PROTEINS - AN OVERVIEW

Plasma and Plasma Derivatives Continue to Dominate Blood Components Market

Table 11. World Plasma Products Market by Geographic Region (2016): Percentage Breakdown of Market Value for Asia-Pacific, Europe, North America and Rest of World (includes corresponding Graph/Chart)

Table 12. World Plasma Products Market by Protein (2016): Percentage Breakdown of Market Value for Albumin, All Factors, IVIG and Others (includes corresponding Graph/Chart)

Table 13. Leading Players in the Global Plasma Market (2016): Percentage Breakdown of Market Value for CSL, Grifols, Octapharma, Shire and Others (includes corresponding Graph/Chart)

Table 14. Leading Players in Plasma Fractionation by Capacity (2017 & 2022): Percentage Breakdown of Annual Capacity for CSL, Grifols, Kedrion, Octapharma, Shire and Others (includes corresponding Graph/Chart)

Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW

5. RECENT INDUSTRY ACTIVITY

LFB Group’s 10% IVIg Gains More Approvals in Europe
CSL Acquires Majority Stake in Ruide
Baxter Acquires Claris Injectables
ADMA Biologics Takes Over BTBU
Green Cross Receives FDA Complete Response Letter for IVIG-SN
China Biologic Products Completes Acquisition of Guizhou Taibang
ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial
Kroger Combines Axium Pharmacy and Modern HC
Shire Acquires Baxalta
FDA Accepts BLA for IVIG-SN from Green Cross
Kedrion Bags US Commercial Rights to BIVIGAM
China Biologic Products to Commence Clinical Trials on Next-Gen IVIG Products
FDA Clears ProMetic’s IND for IVIg
LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe
Baxter Divests its BioScience Division
Emergent BioSolutions Acquires Cangene
CMS Begins Evaluation of Payment for In-home IVIG Administration

6. FOCUS ON SELECT PLAYERS

Bharat Serums and Vaccines Limited (India)
Biotest AG (Germany)
China Biologic Products, Inc. (China)
Guizhou Taibang Biological Products Co., Ltd (China)
CSL Limited (Australia)
Grifols, S. A. (Spain)
Hualan Biological Engineering Inc. (China)
Kedrion S. p. A. (Italy)
LFB Group (France)
Octapharma AG (Switzerland)
Shanghai RAAS Blood Products Co., Ltd. (China)
Shire plc (Ireland)
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

7. GLOBAL MARKET PERSPECTIVE

Value Analytics

Table 15. World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 16. World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 17. World 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Volume Analytics

Table 18. World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 19. World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 20. World 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Volume Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Favorable Reimbursement and High Usage Drive Market
Approved and Marketed Human Immunoglobulin Products in the US
Tough Times Ahead for IVIG
ProMetic’s IVIg – A Prospective New Drug in the Crowded Market
Ageing Demographics: A Key Market Driver

Table 21. North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Intravenous Immunoglobulin Reimbursement Scenario
Higher Plasma Center Numbers Key to Secure Raw Material Supply, Costs Remain A Bottleneck

Table 22. Number of Plasma Centers in Operation in the US for Leading Players

Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
US Blood Supply System - A Schematic
Strategic Corporate Developments
B. Market Analytics
Value Analytics

Table 23. The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 24. The US Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Volume Analytics

Table 25. The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 26. The US Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Outlook
ProMetic – Striving towards Plasma Self Sufficiency
Strategic Corporate Development
B. Market Analytics
Value Analytics

Table 27. Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 28. Canadian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Volume Analytics

Table 29. Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 30. Canadian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

3. JAPAN

Market Analysis
Value Analytics

Table 31. Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 32. Japanese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Volume Analytics

Table 33. Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 34. Japanese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Outlook

Table 35. European Immunoglobulin (IVIg and SCIg) Consumption (2016): Per Capita Consumption in Kilograms per Million Inhabitants for Select Leading Countries (includes corresponding Graph/Chart)

Ageing Population Drives Demand

Table 36. Aged Population in the EU (2016): Population Over 65+ Years as % of Total Population (includes corresponding Graph/Chart)

Table 37. Life Expectancy at Birth for Select Countries in Europe: 2016 (includes corresponding Graph/Chart)

Strategic Corporate Developments
B. Market Analytics
Value Analytics

Table 38. European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 39. European Historic Review for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 40. European 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

Volume Analytics

Table 41. European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 42. European Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Outlook
Research Initiative in France
High-dose Intravenous Immunoglobulin to Offer Respite for Primary Sjögren’s Syndrome Patients
LFB Group – A Key Player
B. Market Analytics

Table 43. French Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 44. French Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Outlook
Biotest AG – A Key Player
B. Market Analytics

Table 45. German Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 46. German Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4C. ITALY

A. Market Analysis
Outlook
Kedrion S. p. A. – A Key Player
B. Market Analytics

Table 47. Italian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 48. Italian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

Market Analysis

Table 49. The UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 50. The UK Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4E. SPAIN

A. Market Analysis
Outlook
Grifols, S. A. – A Key Player
B. Market Analytics

Table 51. Spanish Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 52. Spanish Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

4F. REST OF EUROPE

A. Market Analysis
Outlook
PRIVIGEN Debuts in Russia
Key Players
B. Market Analytics

Table 53. Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 54. Rest of Europe Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

Market Analysis
Value Analytics

Table 55. Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 56. Asia-Pacific Historic Review for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 57. Asia-Pacific 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for Australia, China and Rest of Asia-Pacific Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

Volume Analytics

Table 58. Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 59. Asia-Pacific Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)

5A. AUSTRALIA

A. Market Analysis
Overview

Table 60. Australian IVIg Usage by Main Indications (% of grams used annually) (includes corresponding Graph/Chart)

Revised Criteria for Clinical Use of IVIg in Australia
Australian Blood Products Market – An Overview
Australian Red Cross Blood Service
CSL Limited – A Key Player
B. Market Analytics

Table 61. Australian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 62. Australian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

5B. CHINA

A. Market Analysis
Outlook
Overview of Chinese Blood Plasma Market

Table 63. Chinese Plasma Products Market by Product Type (2015): Percentage Breakdown of Value Sales for Albumin, Hyper-immune, IVIg and Others (includes corresponding Graph/Chart)

IVIG – Strong Opportunities Ahead
Domestic Players Rule IVIG Market

Table 64. Chinese IVIG (Intravenous Immunoglobulin) Products Market by Leading Players (2016): Percentage Breakdown of Volume Sales for China Biologic (CBPO), CNBG Shanghai Institute, Hualan Biological, Shanghai RAAS, and Others (includes corresponding Graph/Chart)

Strategic Corporate Developments
Select Key Players
B. Market Analytics

Table 65. Chinese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 66. Chinese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

A. Market Analysis
Outlook
Plasma Fractionation in Southeast Asia – A Focus on Current and Planned Capabilities
Indonesia – An Overview
Bharat Serums And Vaccines Ltd (India) – A Key Player
B. Market Analytics

Table 67. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 68. Rest of Asia-Pacific Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

6. REST OF WORLD

Market Analysis
Value Analytics

Table 69. Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 70. Rest of World Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Volume Analytics

Table 71. Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 72. Rest of World Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes correspomnding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 24 (including Divisions/Subsidiaries - 32)
The United States (11)
Canada (2)
Japan (1)
Europe (8)
  France (1)
  Germany (1)
  The United Kingdom (2)
  Italy (1)
  Spain (1)
  Rest of Europe (2)
Asia-Pacific (Excluding Japan) (9)
Latin America (1)